ASH China Voice丨Zunmin Zhu / Mingfeng Zhao / Wenyi Lu: IL-18 and RQR8 Suicide-Switch Dual-Armored CLL-1 CAR-T Cells Enhance the Efficacy and Safety of AML Therapy 

ASH China Voice丨Zunmin Zhu / Mingfeng Zhao / Wenyi Lu: IL-18 and RQR8 Suicide-Switch Dual-Armored CLL-1 CAR-T Cells Enhance the Efficacy and Safety of AML Therapy 

2025.11.19
The 67th American Society of Hematology (ASH) Annual Meeting will be held from December 6 to 9, 2025, in Orlando, USA. As one of the largest, most influential, and most comprehensive international congresses in hematology, ASH attracts tens of thousands of experts and scholars from around the world each year to share the latest advances and breakthrough research in the field.
2025 FACO | Professors Tetsuya Mitsudomi & Yun Gyoo Lee: Strengthening China–Japan–Korea Collaboration to Address Shared Challenges in Lung Cancer Care

2025 FACO | Professors Tetsuya Mitsudomi & Yun Gyoo Lee: Strengthening China–Japan–Korea Collaboration to Address Shared Challenges in Lung Cancer Care

2025.11.06
China, Japan, and South Korea have long ranked among the countries with the highest incidence of lung cancer worldwide. With a heavy disease burden, urgent unmet medical needs, and remarkably similar disease characteristics, strengthening trilateral collaboration among these East Asian nations is critical to advancing clinical oncology and addressing shared challenges in lung cancer management.
ESMO Hot Topic | Professor Zhang Juliang: Long-Term GeparNuevo Follow-Up Reveals Durable Survival Benefits from Durvalumab Neoadjuvant Therapy in Early Triple-Negative Breast Cancer 

ESMO Hot Topic | Professor Zhang Juliang: Long-Term GeparNuevo Follow-Up Reveals Durable Survival Benefits from Durvalumab Neoadjuvant Therapy in Early Triple-Negative Breast Cancer 

2025.11.05
At the 2025 ESMO Annual Congress, the long-term follow-up results of the GeparNuevo trial (Abstract #292MO) were presented. The data showed that although durvalumab combined with neoadjuvant chemotherapy did not significantly improve the pathological complete response (pCR) rate, it significantly prolonged survival outcomes, including invasive disease-free survival (iDFS), distant disease-free survival (DDFS), and overall survival (OS). Notably, among patients who achieved pCR, the 7-year OS rate reached 100% in the durvalumab group, suggesting that immunotherapy may provide long-term benefits through sustained immune surveillance. Oncology Frontier invited Professor Zhang Juliang from Xijing Hospital, Air Force Medical University, to comment on these findings and discuss strategies for optimizing immunotherapy in early triple-negative breast cancer (TNBC).
A New Chapter in Comprehensive Management of Renal Cell Carcinoma | Professors Youyan Guan and Xiongjun Ye Provide In-Depth Insights

A New Chapter in Comprehensive Management of Renal Cell Carcinoma | Professors Youyan Guan and Xiongjun Ye Provide In-Depth Insights

2025.11.03
On August 22–23, 2025, the 2025 Pujiang Uro-Oncology Conference was held in Shanghai, bringing together leading experts to discuss advances in urologic oncology. This article is based on the pre-conference session presented by Professor Youyan Guan (Cancer Hospital, Chinese Academy of Medical Sciences) and Professor Xiongjun Ye, titled “Comprehensive Management of Renal Cancer Patients.” Their lecture systematically reviewed the evolution of treatment concepts, perioperative and advanced-stage strategies, and the construction of comprehensive management systems, aiming to provide clinical and research colleagues with valuable reference and guidance.